Gareev, I,
Gileva, Y,
Dzidzaria, A,
Beylerli, O,
Pavlov, V,
Agaverdiev, M,
Mazorov, B,
Biganyakov, I,
Vardikyan, A,
Jin, M,
Ahmad, A (2021) of clinical trials dedicated to oncourology have begun, using lnc
RNA as new biomarkers or treatments
Guan, XX,
Zhang, YW,
Gareev, I,
Beylerli, O,
Li, XY,
Lu, GT,
Lv, L,
Hai, X (2021) an inflammatory response of astrocytes. Moreover, PTEN si
RNA counteracted the inflammatory response induced by OGD
Mukhametov, U.,
Lyulin, S.,
Borzunov, D.,
Sufianova, G.,
Shumadalova, A.,
Zhang, D.,
Gareev, I. (2022) RNAs), which are
RNA molecules that are not translated into proteins. The best known of these are microRNAs (mi
. Among all founded lnc
RNA-based therapeutics and non-invasive diagnostic tools, nuclear enriched abundant
Begliarzade, Sema,
Beilerli, Aferin,
Sufianov, Albert,
Tamrazov, Rasim,
Kudriashov, Valentin,
Ilyasova, Tatiana,
Liang, Yanchao,
Beylerli, Ozal (2023) RNAs) that are highly specific
compared to the m
RNA profile and are involved in the regulation of gene expression. Lnc
Beilerli, A.,
Kudriashov, V.,
Sufianov, A.,
Kostin, A.,
Begliarzade, S.,
Ilyasova, T.,
Liang, Ya.,
Mukhamedzyanov, A.,
Beylerli, O. (2023) RNAs) as dynamic modifiers in the pathogenesis of various diseases. MiRNAs are a separate class of
RNA molecules